ANN ARBOR, Mich., Nov. 7, 2006 (PRIMEZONE) -- Pipex Therapeutics, Inc. (OTCBB:SFPH), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that the pivotal clinical trial results of its lead drug candidate, COPREXA(tm) (oral tetrathiomolybdate) a new treatment being developed for initially-presenting neurologic Wilson’s disease, were presented at the Wilson’s Disease Association Annual Meeting in Bethesda, MD.
